Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. director Tami Reller acquired an award of 128,851 restricted stock units on October 1, 2026. Each RSU represents a contingent right to receive one common share. The transaction table reports a direct post-transaction position of 128,851 shares; the footnote identifies the award as RSUs. Under the 2019 Plan and the Non-Employee Director Compensation Policy, 33.33% vest on October 1, 2027, and the remaining 66.67% vest in two equal annual installments.
Health Catalyst, Inc. (HCAT) identifies Tami Reller as a director in an initial beneficial-ownership report.
Health Catalyst, Inc. (HCAT) reported that Chief Executive Officer and director Simeon Kohl received a grant of 2,747,385 restricted stock units (RSUs) on September 14, 2026 under the company’s 2026 Employment Inducement Incentive Plan. 915,975 RSUs vest on September 4, 2027, with the remaining RSUs vesting in eight approximately equal quarterly installments thereafter, subject to plan terms. On the same date, he also purchased 59,000 shares of common stock at $1.7871 per share in a direct transaction. No Rule 10b5-1 trading plan is indicated.
Health Catalyst, Inc. (HCAT) disclosed that Simeon Kohl, its Chief Executive Officer and a director, beneficially owns 25,000 shares of common stock. According to the accompanying footnote, Kohl acquired an aggregate of 25,000 shares on September 11, 2026 through an open market purchase at a weighted average price of $1.76427 per share, and these shares are now held directly.
Health Catalyst, Inc. (HCAT) reported that on September 11, 2026, it appointed Tami Reller to its board of directors as a Class III director, with her service effective October 1, 2026, expanding the board from six to seven members. She will serve as chair of the Audit Committee, replacing Justin Spencer in that role while he remains on the committee, and will join the Compensation Committee, replacing Jill Hoggard Green there. The company highlights Reller’s extensive executive experience at Duly Health and Care, subsidiaries of UnitedHealth Group, and Microsoft, as well as her public-company board service. A contemporaneous press release describes Health Catalyst as an AI-forward healthcare intelligence company built on 18 years of results and $2.8 billion in validated outcomes.
Health Catalyst, Inc. (HCAT) reported that CEO and director Albert Benjamin had 35,244 shares of common stock disposed of on September 10, 2026 at $1.6747 per share to satisfy tax withholding obligations related to vesting Restricted Stock Units. After this tax-withholding transaction, he directly holds 1,388,406 shares of common stock. The sale was executed as a mandatory "sell to cover" under the company’s equity incentive plans and is described as not being a discretionary trade.
Health Catalyst, Inc. (HCAT) is the issuer of common stock covered by a notice filed on behalf of Benjamin Albert under Rule 144. The notice relates to the proposed sale of 35,244 shares of common stock through Morgan Stanley Smith Barney LLC, to be sold on or about September 10, 2026 on NASDAQ.
The filing also lists prior sales of restricted stock by Benjamin Albert during the preceding three months, and states that Health Catalyst, Inc. had 75,256,381 shares of common stock outstanding as of the time indicated.
Health Catalyst, Inc. (HCAT) is the subject of an amended Schedule 13D filing by investment entities affiliated with Palogic, which report beneficial ownership of 5,374,949 shares of common stock, representing 7.1% of the company’s outstanding shares as of July 31, 2026.
The Palogic group—Palogic Value Fund, Palogic Value Management, Palogic Capital Management, and Ryan L. Vardeman—acquired these shares for an aggregate of approximately $11,790,874 in open‑market transactions. On September 4, 2026, Palogic Value Management sent a letter to Health Catalyst’s board applauding the VitalWare sale and requesting a clearer forward‑looking business plan, more detailed and separated R&D cost disclosure, enhanced revenue and business-metric disclosure, and discussion of capital allocation and the path to profitable growth.
Health Catalyst, Inc. (HCAT) announced a leadership transition, appointing Simeon Kohl as Chief Executive Officer, President, principal executive officer and principal operating officer, and as a Class III director effective September 14, 2026, succeeding Ben Albert. Albert will resign as CEO, President and director effective September 13, 2026 and become Chief Business Officer.
Kohl’s offer letter provides a $600,000 base salary, annual bonus target equal to 100% of base salary, Tier 1 participation in the Executive Severance Plan, and a planned grant of 2,747,385 RSUs, including 915,975 RSUs vesting on September 4, 2027 and the remainder in eight quarterly installments. The Board also adopted a new 2026 Employment Inducement Incentive Plan, reserving 2,747,385 shares for awards to new or returning employees under Nasdaq’s inducement award rules. The press release highlights Kohl’s prior leadership of Performant Healthcare through its sale to Machinify for approximately $670 million and notes that Health Catalyst has documented $2.8 billion in outcomes and previously used the Vitalware divestiture to retire an approximately $160 million credit facility.
Health Catalyst, Inc. (symbol: HCAT) is the issuer of record for a Form 4 filing submitted to the SEC. Larson-Green Julie reported acquisition or exercise transactions in this Form 4 filing.
Health Catalyst, Inc. (HCAT) reported that director Julie Larson-Green received an award of 9,766 restricted stock units (RSUs) of common stock under the company’s 2019 Stock Option and Incentive Plan. Each RSU represents one share of common stock, and 100% of the RSUs vested on September 1, 2026, bringing her direct holdings to 185,101 shares. The award was granted at no cash purchase price, and no Rule 10b5-1 trading plan is reported for this transaction.